Altay Therapeutics Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
6
- Latest Deal Type
-
Series A1
- Latest Deal Amount
-
$37M
- Investors
-
13
Altay Therapeutics General Information
Description
Developer of disease-modifying therapies intended to treat neuromuscular diseases and oncology. The company's method targets utilizing novel drug development platforms powered by genetics, AI, and computational biology to treat chronic indications such as rheumatoid arthritis, fibrotic diseases, ulcerative colitis, and liver cancer, enabling researchers to discover small-molecule binding sites within previously undruggable proteins.
Contact Information
Website
www.altaytherapeutics.comCorporate Office
- 733 Industrial Road
- San Carlos, CA 94070
- United States
Corporate Office
- 733 Industrial Road
- San Carlos, CA 94070
- United States
Altay Therapeutics Timeline
Altay Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC (Series A1) | 14-Oct-2026 | $37M | Completed | Clinical Trials - General | ||
| 7. Grant | 12-May-2025 | Completed | Clinical Trials - General | |||
| 6. Later Stage VC | 14-Apr-2024 | Completed | Clinical Trials - General | |||
| 5. Early Stage VC (Series A) | 21-Sep-2022 | Completed | Clinical Trials - General | |||
| 4. Grant | 01-Jun-2022 | Completed | Clinical Trials - General | |||
| 3. Accelerator/Incubator | 18-Mar-2020 | Completed | Startup | |||
| 2. Accelerator/Incubator | 01-Jan-2020 | Completed | Startup | |||
| 1. Accelerator/Incubator | 07-Aug-2019 | Completed | Startup |
Altay Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A 2 | ||||||||
| Series A 1 | ||||||||
| Series A 4 | 4,544,180 | $0.000100 | 8% | $0.03 | $0.03 | 1x | $0.03 | 1.37% |
| Series A 3 | 54,106,654 | $0.000100 | 8% | $0.14 | $0.14 | 1x | $0.14 | 16.3% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Altay Therapeutics Patents
Altay Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4794785-A1 | Carbocyclic and heterocyclic stat3 inhibitor compositions and methods | Pending | 10-Nov-2023 | ||
| WO-2025102082-A1 | Carbocyclic and heterocyclic stat3 inhibitor compositions and methods | Inactive | 10-Nov-2023 | ||
| AU-2024364448-A1 | N-phenyl-3-(2,5-dioxopyrrolidin-1-yl)propanamide derivatives and similar compounds as dux4 inhibitors for the treatment of e.g. neuromuscular disorders | Pending | 20-Oct-2023 | ||
| EP-4795028-A1 | N-phenyl-3-(2,5-dioxopyrrolidin-1-yl)propanamide derivatives and similar compounds as dux4 inhibitors for the treatment of e.g. neuromuscular disorders | Pending | 20-Oct-2023 | ||
| US-20260176256-A1 | N-phenyl-3-(2,5-dioxopyrrolidin-1-yl)propanamide derivatives and similar compounds as dux4 inhibitors for the treatment of e.g. neuromuscular disorders | Pending | 20-Oct-2023 | C07D401/14 |
Altay Therapeutics Signals
Altay Therapeutics Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Biogen | Corporation | Minority | ||
| Fountain Health Partners | Growth/Expansion | Minority | ||
| Global BioAccess Fund | Venture Capital | Minority | ||
| HealthCap | Venture Capital | Minority | ||
| Pappas Capital | Venture Capital | Minority |
Altay Therapeutics FAQs
-
When was Altay Therapeutics founded?
Altay Therapeutics was founded in 2019.
-
Where is Altay Therapeutics headquartered?
Altay Therapeutics is headquartered in San Carlos, CA.
-
What is the size of Altay Therapeutics?
Altay Therapeutics has 6 total employees.
-
What industry is Altay Therapeutics in?
Altay Therapeutics’s primary industry is Biotechnology.
-
Is Altay Therapeutics a private or public company?
Altay Therapeutics is a Private company.
-
What is the current valuation of Altay Therapeutics?
The current valuation of Altay Therapeutics is .
-
What is Altay Therapeutics’s current revenue?
The current revenue for Altay Therapeutics is .
-
How much funding has Altay Therapeutics raised over time?
Altay Therapeutics has raised $43.2M.
-
Who are Altay Therapeutics’s investors?
Biogen, Fountain Health Partners, Global BioAccess Fund, HealthCap, and Pappas Capital are 5 of 13 investors who have invested in Altay Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process